MGNX
MGNX clinical trials: MACROGENICS INC
Every trial on ClinicalTrials.gov where MACROGENICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 54
- Trials linked
- 42
- As lead sponsor
- 12
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MGNX on the catalyst calendar · MGNX registry changes
- Primary completion Sep 2028Sponsor estimatePhase 1NCT07822399A Study of MGC030 in Participants With Advanced Solid TumorsMacroGenics · Urothelial CancerRecruitingMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 1NCT06242470A Study of MGC026 in Participants With Advanced Solid TumorsMacroGenics · Advanced Solid TumorRecruitingMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 1NCT05362773A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesMacroGenics · Leukemia, Acute MyeloidActive, not recruitingMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 2NCT06730347A Study of Lorigerlimab in Participants With Advanced Solid TumorsMacroGenics · Platinum-resistant Ovarian CancerRecruitingMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 19, 2026ActualPhase 2NCT05848011A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerMacroGenics · Androgen-Independent Prostatic CancerCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 1NCT06723236A Study of MGC028 in Participants With Advanced Solid TumorsMacroGenics · Advanced Solid TumorsRecruitingMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 4, 2024ActualPhase 2NCT05551117A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsMacroGenics · Castration-Resistant Prostatic CancerTerminatedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2025ActualPhase 1NCT05293496A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsMacroGenics · Advanced Solid TumorCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2021ActualPhase 1NCT02475213Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerMacroGenics · MelanomaCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 18, 2023ActualPhase 1/Phase 2NCT03729596MGC018 With or Without MGA012 in Advanced Solid TumorsMacroGenics · Squamous Cell Carcinoma of Head and NeckTerminatedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2024ActualPhase 2/Phase 3NCT04082364Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerMacroGenics · Gastric CancerCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2024ActualPhase 1NCT05261191A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral TherapyMacroGenics · Human Immunodeficiency Virus I InfectionCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2024ActualPhase 1NCT03761017MGD019 DART® Protein in Unresectable/Metastatic CancerMacroGenics · Squamous Cell Non Small Cell Lung CancerCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2021ActualPhase 1/Phase 2NCT02689284Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction CancerMacroGenics · Gastric CancerCompletedMGNXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2021ActualPhase 3NCT02492711Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerMacroGenics · HER-2 Positive Breast CancerCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2016ActualPhase 2NCT01828021Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerMacroGenics · Breast CancerCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 14, 2022ActualPhase 1NCT01148849Safety Study of MGAH22 in HER2-positive CarcinomasMacroGenics · Breast CancerCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 5, 2022ActualPhase 1/Phase 2NCT02152956Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)MacroGenics · AMLTerminatedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2023ActualPhase 1NCT03219268A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsMacroGenics · Advanced Solid TumorsCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2022ActualPhase 2NCT04634825Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerMacroGenics · Head and Neck CancerTerminatedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2012ActualPhase 3NCT00920582Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusMacroGenics · Type 1 Diabetes MellitusTerminatedMGNXLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2010ActualPhase 2/Phase 3NCT00385697The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusMacroGenics · Type 1 Diabetes MellitusCompletedMGNXLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2009ActualPhase 2NCT00625586Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic CancerMacroGenics · Pancreatic CancerTerminatedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2011ActualNo phase registeredNCT00870818Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)MacroGenics · Type 1 Diabetes MellitusTerminatedMGNXLeadLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2021ActualPhase 1NCT03570918MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral TherapyMacroGenics · HIV-1-infectionCompletedMGNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 29 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner